Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
Suzanne Trudel(Princess Margaret Cancer Centre), Simon J. Harrison(Peter MacCallum Cancer Centre), Luciano J. Costa(University of Alabama at Birmingham), Sheeba K. Thomas(The University of Texas MD Anderson Cancer Center), Mengsong Li, Teiko Sumiyoshi(Universidad San Carlos), Rayan Kaedbey(Jewish General Hospital), Divya Samineni, Adam D. Cohen(Penn Center for AIDS Research), María‐Victoria Mateos(Hospital Clínico San Carlos), Joshua Richter(Tisch Hospital), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), James Cooper, Peter A. Forsberg(University of Colorado Denver), Jacob P. Laubach(Harvard University), Jesús G. Berdeja(Tennessee Oncology), Anjali Vaze, Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Voleak Choeurng, Chihunt Wong, Andrew Spencer(The Alfred Hospital), Amrita Krishnan(City of Hope), Rafaël Fonseca(Mayo Clinic in Arizona)
Cited by 161
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k